# OnCo record paper-vistogard-cancer-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-vistogard-cancer-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-vistogard-cancer-2017" ;
  schema:name "Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity"@en ;
  schema:description "The combined report of the Vistogard studies: 96 percent of patients treated with oral uridine triacetate after a fluorouracil or capecitabine overdose survived, where 84 percent of an earlier supportive-care group had died."@en ;
  schema:url <https://onco.cc/key-papers/paper-vistogard-cancer-2017/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1002/cncr.30321>, <https://pubmed.ncbi.nlm.nih.gov/27622829/>, <https://clinicaltrials.gov/study/NCT01432301> ;
  schema:sameAs <https://doi.org/10.1002/cncr.30321> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Ma WW, Saif MW, El-Rayes BF, et al." ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:drugs <https://onco.cc/drugs/uridine-triacetate/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:companies <https://onco.cc/companies/serb-pharmaceuticals/> ;
  onco:trials <https://onco.cc/trials/vistogard-studies-1-2/> ;
  onco:journals <https://onco.cc/journals/cancer-wiley/> .